therapies against pathogenetically discrete tumor types with supreme efficiency but with minutest toxicity issues. Therefore, the molecular features underlying the disease are of key importance to rationalize a mechanistic approach for target dependent therapy.
therapies against pathogenetically discrete tumor types with supreme efficiency but with minutest toxicity issues. Therefore, the molecular features underlying the disease are of key importance to rationalize a mechanistic approach for target dependent therapy.